China’s Tot Biopharm Secures First Antibody Approval With Avastin Biosimilar

Regulator NMPA Approves Pusintin Biosimilar Product For Cancer Indications

China - Suzhou City
Tot has manufacturing in the Suzhou Industrial Park • Source: Shutterstock

More from Biosimilars

More from Products